137 related articles for article (PubMed ID: 14520129)
1. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
Rynn M; García-España F; Greenblatt DJ; Mandos LA; Schweizer E; Rickels K
J Clin Psychopharmacol; 2003 Oct; 23(5):505-8. PubMed ID: 14520129
[TBL] [Abstract][Full Text] [Related]
2. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy.
Rickels K; DeMartinis N; García-España F; Greenblatt DJ; Mandos LA; Rynn M
Am J Psychiatry; 2000 Dec; 157(12):1973-9. PubMed ID: 11097963
[TBL] [Abstract][Full Text] [Related]
3. Is buspirone effective for panic disorder?
Sheehan DV; Raj AB; Sheehan KH; Soto S
J Clin Psychopharmacol; 1990 Feb; 10(1):3-11. PubMed ID: 2407755
[TBL] [Abstract][Full Text] [Related]
4. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
Modigh K; Westberg P; Eriksson E
J Clin Psychopharmacol; 1992 Aug; 12(4):251-61. PubMed ID: 1527228
[TBL] [Abstract][Full Text] [Related]
5. Is imipramine or buspirone treatment effective in patients wishing to discontinue long-term benzodiazepine use?
Sontheimer DL; Ables AZ
J Fam Pract; 2001 Mar; 50(3):203. PubMed ID: 11252203
[No Abstract] [Full Text] [Related]
6. Buspirone in the long-term treatment of generalized anxiety disorder.
Feighner JP
J Clin Psychiatry; 1987 Dec; 48 Suppl():3-6. PubMed ID: 3320034
[TBL] [Abstract][Full Text] [Related]
7. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
[TBL] [Abstract][Full Text] [Related]
8. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report.
Sheehan DV; Raj AB; Sheehan KH; Soto S
Pharmacol Biochem Behav; 1988 Apr; 29(4):815-7. PubMed ID: 3413203
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone.
Pohl R; Balon R; Yeragani VK; Gershon S
Psychopathology; 1989; 22 Suppl 1():60-7. PubMed ID: 2657839
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study.
Lee ST; Park JH; Kim M
Headache; 2005 Sep; 45(8):1004-11. PubMed ID: 16109114
[TBL] [Abstract][Full Text] [Related]
11. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment.
Nardi AE; Freire RC; Valença AM; Amrein R; de Cerqueira AC; Lopes FL; Nascimento I; Mezzasalma MA; Veras AB; Sardinha A; de Carvalho MR; da Costa RT; Levitan MN; de-Melo-Neto VL; Soares-Filho GL; Versiani M
J Clin Psychopharmacol; 2010 Jun; 30(3):290-3. PubMed ID: 20473065
[TBL] [Abstract][Full Text] [Related]
12. Cognitive-behavioral therapy for benzodiazepine discontinuation in panic disorder patients.
Otto MW; Pollack MH; Meltzer-Brody S; Rosenbaum JF
Psychopharmacol Bull; 1992; 28(2):123-30. PubMed ID: 1355299
[TBL] [Abstract][Full Text] [Related]
13. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
14. Buspirone in clinical practice.
Rickels K
J Clin Psychiatry; 1990 Sep; 51 Suppl():51-4. PubMed ID: 2211569
[TBL] [Abstract][Full Text] [Related]
15. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.
Mercier-Guyon C; Chabannes JP; Saviuc P
Curr Med Res Opin; 2004 Sep; 20(9):1347-55. PubMed ID: 15383182
[TBL] [Abstract][Full Text] [Related]
16. Medication discontinuation in panic disorder.
Ballenger JC
J Clin Psychiatry; 1992 Mar; 53 Suppl():26-31. PubMed ID: 1548252
[TBL] [Abstract][Full Text] [Related]
17. Comorbid cannabis use and panic disorder: short term and long term follow-up study.
Dannon PN; Lowengrub K; Amiaz R; Grunhaus L; Kotler M
Hum Psychopharmacol; 2004 Mar; 19(2):97-101. PubMed ID: 14994319
[TBL] [Abstract][Full Text] [Related]
18. Specific responses to imipramine and doxepin in psychoneurotic depressed patients with sleep disturbance.
Finnerty RJ; Goldberg HL
J Clin Psychiatry; 1981 Jul; 42(7):275-9. PubMed ID: 7240113
[TBL] [Abstract][Full Text] [Related]
19. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
[TBL] [Abstract][Full Text] [Related]
20. Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients.
Koh KB; Lee Y
Psychother Psychosom; 2004; 73(5):286-92. PubMed ID: 15292626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
